[Erythropoietin and erythropoiesis inhibition factor in the newborn and infants with cyanotic heart abnormalities].
In the present study, hematocrit, pO2 in the capillary blood, reticulocyte count, erythropoietin activity in plasma and activity of the erythropoiesis inhibition factor in 24-h collective urine were determined in newborns and infants with cyanotic malformations of the heart (transpositions of the big arteries). The plasma of the healthy newborns shows immediately after birth an erythropoietin activity below 1%, as measured by the 59Fe incorporation. The erythropoietin activity of the plasma of infants with cyanotic malformations of the heart is enhanced up to the 14th day of life. In the period of day 14--30 it corresponds to the values of healthy newborns despite the persistence of hypoxia. After the 30th day of life there is again demonstrable an increased erythropoietin activity in the plasma of infants with cyanotic malformations of the heart. Obviously, the low values of 59Fe incorporation from day 14--30 are due to the occurrence of the erythropoiesis inhibition factor. In the urine of infants with cyanotic malformations of the heart there could be demonstrated distinct inhibitions of the stimulated erythropoiesis of the polycythemic mouse. The present studies suggest that the erythropoiesis inhibition factor occurs in postnatal development irrespectively of the degrees of O2-supply of the tissue, and is possibly dependent on the gestational age.
D000375:Aging; D000818:Animals; D001681:Biological Assay; D001798:Blood Proteins / Q000652:urine*; D002196:Capillaries; D004906:Erythrocyte Count; D004921:Erythropoietin / Q000097:blood*; D006400:Hematocrit; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D051379:Mice; D010100:Oxygen / Q000097:blood; D010313:Partial Pressure; D012156:Reticulocytes / Q000166:cytology; D014188:Transposition of Great Vessels / Q000097:blood* / Q000652:urine
D001798:Blood Proteins; C007627:erythropoiesis inhibiting factors; D004921:Erythropoietin; D010100:Oxygen
Erythropoietin und Erythropoesehemmfaktor bei Neugeborenen und Süglingen mit zyanotischen Herzmissbildungen.